Phathom Pharmaceuticals announced its participation in Digestive Disease Week 2026, where it will present clinical and real-world data on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker for GERD treatment. The company reported Q1 2026 net revenues of $58.3 million, representing 104% year-over-year growth, with 1.35 mill...

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP in...

U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose ...

Phathom Pharmaceuticals priced a $130 million underwritten public offering consisting of 6.875 million shares of common stock at $16.00 per share and 1.25 million pre-funded warrants at $15.999 per warrant. The offering is expected to close on January 9, 2026, with net proceeds intended for general corporate purposes including working capital, co...

Phathom Pharmaceuticals will participate in the American College of Gastroenterology's 2025 Annual Scientific Meeting, showcasing VOQUEZNA® (vonoprazan) as an approved treatment for Gastroesophageal Reflux Disease (GERD) through product theater presentations and exhibit booth interactions.